Basisstatistiken
| LEI | 967600VLQ0ZC2HSOG765 |
| CIK | 1651625 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AC Immune SA
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal E |
|
| May 15, 2026 |
Exhibit 99.3 |
|
| May 15, 2026 |
Exhibit 99.1 INVITATION TO THE ANNUAL GENERAL MEETING 2026 to the Shareholders of AC Immune SA Thursday, 11 June 2026 2:30pm CEST 8:30am EST Our goal is global leadership in Precision Prevention for the diagnosis and treatment of neurodegenerative diseases we are executing a clear business strategy focusing on: ACI - 35 Active immunotherapy against pTau in a prevention study for pre - symptomatic |
|
| May 15, 2026 |
Exhibit 99.2 |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal E |
|
| May 12, 2026 |
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Exhibit 99.1 AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM · Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure · Board Chair, Martin Zügel, MD, to be appointed interim CEO · Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board · Company well-positioned to drive sho |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| April 30, 2026 |
AC Immune First Quarter 2026 Financial and Corporate Updates Exhibit 99.1 PRESS RELEASE AC Immune First Quarter 2026 Financial and Corporate Updates · Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 · Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately t |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| April 30, 2026 |
Exhibit 99.1 PRESS RELEASE AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease · Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone payment · Allows evaluation of potential for precision prevention of neurodegenerative diseases · Data from ABATE Cohorts AD1, AD2 and AD3 after 12 month |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| April 7, 2026 |
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Exhibit 99.1 PRESS RELEASE AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly · Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small molecules · Investigational New Drug (IND)-enabling studies to commence in H1 2026 Lausanne, Switzerland, April 7, 2026 - AC Immu |
|
| March 13, 2026 |
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update ● Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson’s disease ● NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed ● Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer’s disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026 ● Cash resources of CHF 91. |
|
| March 13, 2026 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2025 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Andrea Pfe |
|
| March 13, 2026 |
Exhibit 4.20 |
|
| March 13, 2026 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Audited consolidated financial statements — AC IMMUNE SA Report of the statutory auditor 2 Consolidated Balance Sheets as of December 31, 2025 and 2024 8 Consolidated Statements of Income/(Loss) and Consolidated Statements of Comprehensive Income/(Loss) for the fiscal years ended December 31, 2025, 2024 and 2023 9 Consolidated Statements of Changes in Equ |
|
| March 13, 2026 |
Exhibit 3.1 Béatrice EHLERS NOTAIRE STATUTS de AC lmmune SA (AC lmmune AG) (AC lmmune Ltd) société anonyme ayant son siège à Ecublens (Vaud) tF**rl.* du 6 mars 2026 ***** ARTICLES OF ASSOCIATION of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these Articles of Association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune t |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| March 13, 2026 |
, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents , UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2026 |
Table of Contents Statutory Financial Statements (Swiss CO) December 31, 2025 Report of the statutory auditor 2 Statutory Balance Sheets 9 Statutory Income Statements 10 Notes to the Statutory Financial Statements Proposed Carry Forward of the Accumulated Losses 11 23 AC Immune SA EPFL Innovation Park 1015 Lausanne / Ecublens Switzerland Statutory Financial Statements 1 Table of Contents Report of |
|
| March 13, 2026 |
Exhibit 12.2 CERTIFICATION I, Christopher Roberts, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 13, 2026 |
Exhibit 12.1 CERTIFICATION I, Andrea Pfeifer, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| March 13, 2026 |
Compensation Report in accordance with Article 734 para. 1 of the Swiss Code of Obligations (CO) Compensation Report in accordance with Article 734 para. 1 of the Swiss Code of Obligations (CO) Contents ● Report of the Statutory Auditor ● Compensation of the Board of Directors ● Compensation of the Members of the Executive Management ● Equity Incentive Plans of the Board of Directors and the Members of the Executive Management ● Mandates outside AC Immune SA ● Compensation Philosophy, Princip |
|
| March 13, 2026 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2025 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Christophe |
|
| March 13, 2026 |
Exhibit 4.19 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 13, 2026. The following description of the terms of our common shares is not meant to be co |
|
| March 13, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-227016, No. 333-249655 and No. 333-277940) and on Form S-8 (No. 333-216539, No. 333-213865 and No. 333-233019) of AC Immune SA of our report dated March 13, 2026 relating to the financial statements and the effectiveness of in |
|
| March 13, 2026 |
Exhibit 11.1 AC IMMUNE SA Policy Concerning Trading in Company Securities Adopted September 22, 2016 Revised February 16, 2017 Revised April 27, 2021 Revised December 6, 2024 A. Introduction It is the policy of AC Immune SA (the “Company”) that it will, without exception, comply with all applicable laws and regulations in conducting its business. When carrying out Company business, employees and d |
|
| February 24, 2026 |
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor Exhibit 99.1 PRESS RELEASE AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor · ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor · NLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseases · ACI-19764 is an important addition to AC Immune’s growing sma |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princi |
|
| December 11, 2025 |
Exhibit 99.1 PRESS RELEASE AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease · Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s disease · Clear safety profile with no clinically relevant safety issues reported · Targets met |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| November 4, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and ni |
|
| November 4, 2025 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2025 2024 Assets Non-current assets Property, plant and equipment 5 2,208 2,651 Right-of-use assets 6 4,653 5,437 Intangible asset 8 50,416 50,416 Long-term financial assets 6 584 415 Total non-current assets 57,861 58,919 Current assets Prepaid expenses 9 3,294 4,302 Accrued inc |
|
| November 4, 2025 |
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update ● Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn ● Cash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| October 3, 2025 |
144 0001697107 XXXXXXXX LIVE 0001651625 AC IMMUNE SA 001-37891 EPFL Innovation Park, Building B Lausanne V8 00000 41213459121 ANDREA M. |
|
| September 12, 2025 |
144 0001697107 XXXXXXXX LIVE 0001651625 AC IMMUNE SA 001-37891 EPFL Innovation Park, Building B Lausanne V8 00000 41213459121 ANDREA M. |
|
| September 4, 2025 |
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Exhibit 99.1 PRESS RELEASE AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway · Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30% · Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer’s and Parkinson’s diseases and progres |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| August 5, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and si |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| August 5, 2025 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2025 2024 Assets Non-current assets Property, plant and equipment 5 2,490 2,651 Right-of-use assets 6 4,926 5,437 Intangible asset 8 50,416 50,416 Long-term financial assets 6 584 415 Total non-current assets 58,416 58,919 Current assets Prepaid expenses 9 2,542 4,302 Accrued income 5 |
|
| August 5, 2025 |
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update ● Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ● ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| June 20, 2025 |
Exhibit 99.1 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission Investor Update NASDAQ: ACIU | Annual General Meeting – June 19, 2025 PIONEERING PRECISION MEDICINE TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES Disclaimer 2 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission Thi |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| May 19, 2025 |
Exhibit 99.3 |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| May 19, 2025 |
Exhibit 99.2 |
|
| May 19, 2025 |
Exhibit 99.1 INVITATION TO THE ANNUAL GENERAL MEETING 2025 to the Shareholders of AC Immune SA Thursday, 19 June 2025 2:00pm CEST 8:00am EST Our goal is global leadership in Precision Medicine for the diagnosis and treatment of neurodegenerative diseases we are executing a clear business strategy built on three pillars: alzheimer’s disease accelerate development of novel therapeutics in ad with ou |
|
| April 30, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three months |
|
| April 30, 2025 |
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update ● Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases ● Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkin |
|
| April 30, 2025 |
(AC Immune AG) (AC Immune Ltd) Exhibit 99.4 (AC Immune AG) (AC Immune Ltd) (AC Immune AG) (AC Immune Ltd) Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these Articles of Association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I. Corporate Name, |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| April 30, 2025 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2025 2024 Assets Non-current assets Property, plant and equipment 5 2,761 2,651 Right-of-use assets 6 5,186 5,437 Intangible asset 8 50,416 50,416 Long-term financial assets 6 585 415 Total non-current assets 58,948 58,919 Current assets Prepaid expenses 9 3,607 4,302 Accrued income |
|
| March 13, 2025 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Christophe |
|
| March 13, 2025 |
, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents , UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-277940) and on Form S-8 (No. 333-216539, No. 333-213865 and No. 333-233019) of AC Immune SA of our report dated March 13, 2025 relating to the financial statements and the effectiveness of internal control over financial repor |
|
| March 13, 2025 |
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Exhibit 99.1 PRESS RELEASE AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update · Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization · ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerab |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| March 13, 2025 |
Exhibit 12.2 CERTIFICATION I, Christopher Roberts, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 13, 2025 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Andrea Pfe |
|
| March 13, 2025 |
Exhibit 11.1 AC IMMUNE SA Policy Concerning Trading in Company Securities Adopted September 22, 2016 Revised February 16, 2017 Revised April 27, 2021 Revised December 6, 2024 A. Introduction It is the policy of AC Immune SA (the “Company”) that it will, without exception, comply with all applicable laws and regulations in conducting its business. When carrying out Company business, employees and d |
|
| March 13, 2025 |
Exhibit 4.19 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 13, 2025. The following description of the terms of our common shares is not meant to be co |
|
| March 13, 2025 |
Exhibit 12.1 CERTIFICATION I, Andrea Pfeifer, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| December 13, 2024 |
ACIU / AC Immune SA / AFFiRiS AG - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 y1211240sc13ga3.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) AC IMMUNE SA (Name of Issuer) Common Shares (Title of Class of Securities) H00263105 (CUSIP Number) May 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| December 10, 2024 |
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome Exhibit 99.1 Press Release AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome · ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug · No cases of amyloid-related imaging abnormalities observed in this study population · Based upon these findings, AC Immune plans to |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga807422aciu11142024.htm AMENDMENT NO. 8 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 8)1 AC Immune SA (Name of Issuer) Common Shares, nominal value CHF 0.0 |
|
| November 14, 2024 |
Exhibit 99.1 Press Release AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease · Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations · 100% of patients receiving ACI-7104.056 responded against the target antigen · ACI-7104.056 is |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| November 5, 2024 |
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ● ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and immunogenicity data ● Prescreening rate for Phase 2b ReTain trial of JNJ-2056 (ACI-35.030) in Alzheimer’s disease (AD) triggered CHF 24.6 million milestone under agreement ● JNJ-2056 r |
|
| November 5, 2024 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 2,736 3,376 Right-of-use assets 6 3,091 3,508 Intangible asset 8 50,416 50,416 Long-term financial assets 6 415 361 Total non-current assets 56,658 57,661 Current assets Prepaid expenses 9 3,446 6,437 Accrued inc |
|
| November 5, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and ni |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Prin |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Prin |
|
| September 17, 2024 |
Exhibit 99.1 Press Release AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Re𝜏ain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease · Prescreening rate of Phase 2b Re𝜏ain trial triggers clinical development milestone payment in September · Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD · FDA Fast |
|
| August 28, 2024 |
Exhibit 99.1 Press Release AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions · PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI · This Fast Track designation applies across Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration · Follows two previous Fast Track desi |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| August 6, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-277940 PROSPECTUS SUPPLEMENT (To Prospectus dated July 31, 2024) Up to $80,000,000 We have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated August 6, 2024, relating to our common shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms |
|
| August 6, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and si |
|
| August 6, 2024 |
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update ● Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential milestones of up to approximately $2.1 billion ● ACI-24.060 ABATE Phase 2 trial in Alzheimer’s disease (AD) on track with enrolment expectations ● ACI-7 |
|
| August 6, 2024 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 2,926 3,376 Right-of-use assets 6 3,235 3,508 Intangible asset 8 50,416 50,416 Long-term financial assets 6 415 361 Total non-current assets 56,992 57,661 Current assets Prepaid expenses 9 3,864 6,437 Accrued income 4 |
|
| August 6, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 6, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: AC Immune SA, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland, with registered seat in Ecublens (VD), Switzerland (the “Company”), proposes, subject to the conditions stated herein, to sell from time to time through Jeff |
|
| August 6, 2024 |
OPTION AND LICENSE AGREEMENT AC Immune SA TAKEDA PHARMACEUTICALS, USA, INC. Dated as of May 11, 2024 EXECUTION VERSION [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| July 31, 2024 |
Exhibit 99.1 Press Release AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 · morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS · morADC demonstrated significant synergies, |
|
| July 29, 2024 |
July 29, 2024 Re: AC Immune SA Registration Statement on Form F-3 Filed on March 14, 2024 Registration No. |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024 As filed with the Securities and Exchange Commission on July 26, 2024 Registration No. |
|
| July 26, 2024 |
EX-3.1 2 dp215008ex0301.htm EXHBIIT 3.1 Exhibit 3.1 Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these Articles of Association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I. Corporate Name, Principal Office, Durat |
|
| July 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) AC Immune SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forw |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| July 25, 2024 |
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Exhibit 99.1 Press Release AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease · Treatment of first randomized person with preclinical AD expected this quarter · Phase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pione |
|
| June 20, 2024 |
Exhibit 99.1 NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Investor Update NASDAQ: ACIU | Annual General Meeting – June 20, 2024 PIONEERING PRECISION MEDICINE TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES Exhibit 99.1 NASDAQ: ACIU | AGM Presentation, June 2024 © 2024 AC Immune. Not to be used or reproduced without permission Dis |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal |
|
| May 21, 2024 |
Exhibit 99.2 1 U P X AC Immune SA Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 0405UC + + q IF VOTING BY MAIL, SIGN, DETACH AND RETURN BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Annual General Meeting Proxy Card *Please see reverse side for additional proposals and required signature. Proposals - The Board of Directors |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal |
|
| May 21, 2024 |
Exhibit 99.1 INVITATION TO THE ANNUAL GENERAL MEETING 2024 to the Shareholders of AC Immune SA Thursday, 20 June 2024 2:30pm CEST 8:30am EDT Our goal is global leadership in Precision Medicine for the diagnosis and treatment of neurodegenerative diseases We are executing a clear business strategy built on three pillars: Accelerate development of novel therapeutics in Alzheimer’s disease (AD) Expan |
|
| May 13, 2024 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 3,236 3,376 Right-of-use assets 6 3,341 3,508 Intangible asset 8 50,416 50,416 Long-term financial assets 6 415 361 Total non-current assets 57,408 57,661 Current assets Prepaid expenses 9 3,917 6,437 Accrued income |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 13, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| May 13, 2024 |
Exhibit 99.1 Bettter Health, Brighter Future News Release AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease − Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to receive |
|
| May 13, 2024 |
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update ● Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion ● ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloi |
|
| May 13, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three months |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| March 19, 2024 |
United States securities and exchange commission logo March 19, 2024 Christopher Roberts Chief Financial Officer AC Immune USA, Inc. |
|
| March 14, 2024 |
ANNU AL REPORT 2023Our goal is global leadership in Precision Medicine for the diagnosis and treatment of neurodegenerative diseases We are executing a clear business strategy built on three pillars: Accelerate development of novel therapeutics in AD with our partners Expand our strategic focus in Parkinson’s disease (PD) and non-AD neurodegenerative diseases, including NeuroOrphan indications and |
|
| March 14, 2024 |
Exhibit 12.1 CERTIFICATION I, Andrea Pfeifer, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| March 14, 2024 |
Consolidated Balance Sheets (In CHF thousands) Exhibit 99.1 PRESS RELEASE AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update · ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 · ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2 · ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designation · ACI-35.030 ReTain Phase 2b program in |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| March 14, 2024 |
AC IMMUNE SA as the Company as Trustee Senior Indenture Dated as of , 20 TABLE OF CONTENTS Exhibit 4.2 AC IMMUNE SA as the Company and as Trustee Senior Indenture Dated as of , 20 TABLE OF CONTENTS Page Article DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 5 Section 1.02. Other Definitions 8 Section 1.03. Incorporation by Reference of Trust Indenture Act 9 Section 1.04. Rules of Construction 9 Article 2 THE SECURITIES Section 2.01. Form and Dating 10 Section 2.02. |
|
| March 14, 2024 |
Exhibit 4.17 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 14, 2024. The following description of the terms of our common shares is not meant to be co |
|
| March 14, 2024 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Andrea Pfe |
|
| March 14, 2024 |
AC IMMUNE SA as the Company as Trustee Subordinated Indenture Dated as of , 20 TABLE OF CONTENTS Exhibit 4.3 AC IMMUNE SA as the Company and as Trustee Subordinated Indenture Dated as of , 20 TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 6 Section 1.04. Rules of Construction 6 Article 2 THE SECURITIES Section 2.01. Form and Dating 6 Sectio |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Exhibit 12.2 CERTIFICATION I, Christopher Roberts, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 14, 2024 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Christophe |
|
| March 14, 2024 |
, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents , UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2024 |
AC Immune SA COMPENSATION RECOUPMENT POLICY Exhibit 97.1 AC Immune SA COMPENSATION RECOUPMENT POLICY This Compensation Recoupment Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of AC Immune (the “Company”) on October 6, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting require |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) AC Immune SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forw |
|
| March 14, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-249655 and No. 333-255576) and on Form S-8 (No 333-216539, No 333-213865 and No. 333-233019) of AC Immune SA of our report dated March 14, 2024 relating to the financial statements and the effectiveness of internal control ove |
|
| March 14, 2024 |
(AC Immune AG) (AC Immune Ltd) Exhibit 3.1 (AC Immune AG) (AC Immune Ltd) (AC Immune AG) (AC Immune Ltd) Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these articles of association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I. Corporate Name, P |
|
| February 9, 2024 |
ACIU / AC Immune SA / AFFiRiS AG - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 p129241sc13ga2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) AC IMMUNE SA (Name of Issuer) Common Shares (Title of Class of Securities) H00263105 (CUSIP Number) December 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princi |
|
| January 22, 2024 |
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Exhibit 99.1 PRESS RELEASE AC Immune to Regain Global Rights to Crenezumab and Semorinemab ● Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies ● Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-st |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princi |
|
| January 3, 2024 |
Exhibit 99.1 PRESS RELEASE AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's diseases · ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to complete cohort 3 in January; 6-month and 12-month amyloid PET data expected in H1 & H2 2024, respectively · ReTain Phase 2b clinical trial of ACI-35.030 i |
|
| December 19, 2023 |
SC 13G/A 1 sc13ga707422aciu12192023.htm AMENDMENT NO. 7 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 7)1 AC Immune SA (Name of Issuer) Common Shares, nominal value CHF 0.0 |
|
| December 19, 2023 |
14,300,000 Common Shares AC IMMUNE SA UNDERWRITING AGREEMENT Exhibit 1.1 14,300,000 Common Shares AC IMMUNE SA UNDERWRITING AGREEMENT December 15, 2023 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 As Representatives of the several Underwriters Ladies and Gentlemen: Introductory. AC Immune SA, a company established in Ecublens, Canton of Vaud, Switzerla |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| December 15, 2023 |
Exhibit 107 The prospectus to which this Exhibit is attached is a final prospectus for the related offering(s). The maximum aggregate offering price of the related offering(s) is $50,050,000. |
|
| December 15, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-255576 PROSPECTUS SUPPLEMENT (To Prospectus dated April 28, 2021) 14,300,000 Common Shares We are offering 14,300,000 of our common shares as part of this offering (the “Public Offering”). Our common shares trade on The Nasdaq Global Market under the trading symbol “ACIU”. On December 14, 2023, the last sale price of our common shares as report |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| December 15, 2023 |
Exhibit 99.1 Press Release AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial · Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD) · Anti-pTau active immunotherapy being designed to potentially |
|
| December 1, 2023 |
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Exhibit 99.1 Press Release AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO · Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO · Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover · Christopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| November 3, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and ni |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| November 3, 2023 |
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update ● Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024 ● ACI-24.060 ABATE interim safety and immunogenicity data in Alzheimer’s disease (AD) expected by year-end ● ACI-7104.056 alpha-synucl |
|
| November 3, 2023 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2023 2022 Assets Non-current assets Property, plant and equipment 5 3,627 4,259 Right-of-use assets 6 2,403 2,808 Intangible asset 9 50,416 50,416 Long-term financial assets 6 361 361 Total non-current assets 56,807 57,844 Current assets Prepaid expenses 10 5,534 4,708 Accrued in |
|
| August 4, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and si |
|
| August 4, 2023 |
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update ● Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD) ● Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clear |
|
| August 4, 2023 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of June 30, December 31, Note 2023 2022 Assets Non-current assets Property, plant and equipment 5 3,760 4,259 Right-of-use assets 6 2,539 2,808 Intangible asset 9 50,416 50,416 Long-term financial assets 6 361 361 Total non-current assets 57,076 57,844 Current assets Prepaid expenses 10 5,167 4,708 Accrued income |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| July 26, 2023 |
AC Immune SA Appoints New Chief Medical Officer Exhibit 99.1 Press Release AC Immune SA Appoints New Chief Medical Officer · Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will joi |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| June 27, 2023 |
Exhibit 99.1 Press Release AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease · Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigational New Drug (IND) clearance for ACI-24.060 · Dosed first individual with Down syndrome (DS) in the DS cohort of ABATE · Interim safety and immunog |
|
| June 26, 2023 |
AC Immune Holds Annual General Meeting of Shareholders Exhibit 99.2 Press Release AC Immune Holds Annual General Meeting of Shareholders · Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting pe |
|
| June 26, 2023 |
Exhibit 99.3 Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these articles of association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I. Corporate Name, Principal Office, Duration and Purpose of the Company I. rAISO |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal |
|
| June 26, 2023 |
Exhibit 99.1 NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting, June 23, 2023 www.acimmune.com Version: 19.06.2023 NASDAQ: ACIU | AGM Presentation, June 2023 © 2023 AC Immune. Not to be used or reproduced without permission Disclaimer This presentatio |
|
| May 24, 2023 |
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA Exhibit 99.1 Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA Da te Friday, 23 June 2023 | 2:30pm CET | 8:30am EDT 2 Contents 4 Letter to Shareholders 7 Overview 9 Agenda and proposals 15 Organizational notes 19 Say on Pay Shareholder information on compensation proposal 3 Dear Shareholders, We are pleased to announce AC Immune’s 7th Annual General Meeting (AGM) as |
|
| May 24, 2023 |
Exhibit 99.2 1 U P X AC Immune SA Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 0 3TUFD + + q IF VOTING BY MAIL, SIGN, DETACH AND RETURN BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Annual General Meeting Proxy Card Proposals - The Board of Directors of the Company recommends that you vote your shares “FOR” Agenda Items 1 |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| April 28, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three months |
|
| April 28, 2023 |
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update Exhibit 99.3 PRESS RELEASE AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ● ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease (AD) cohort in ABATE Phase 1b/2 trial; ● Further ABATE immunogenicity and safety data in higher dose AD cohorts expected in H2 2023 with amyloid-beta-PET imaging data in H1 20 |
|
| April 28, 2023 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2023 2022 Assets Non-current assets Property, plant and equipment 5 4,011 4,259 Right-of-use assets 6 2,674 2,808 Intangible asset 8 50,416 50,416 Long-term financial assets 6 361 361 Total non-current assets 57,462 57,844 Current assets Prepaid expenses 9 5,438 4,708 Accrued income |
|
| April 28, 2023 |
(AC Immune AG) (AC Immune Ltd) 1 Exhibit 99.4 (AC Immune AG) (AC Immune Ltd) (AC Immune AG) (AC Immune Ltd) Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these articles of association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I.Corporate Name, |
|
| March 16, 2023 |
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Press Release AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update · Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 · ACI-24.060 anti-amyloid-beta vaccine for Alzheimer’s disease (AD) showed positive initial safety and immunogenicit |
|
| March 16, 2023 |
, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents , UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2023 |
Exhibit 4.17 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 16, 2023. The following description of the terms of our common shares is not meant to be co |
|
| March 16, 2023 |
Exhibit 4.6 INDEMNITY AGREEMENT (“the Agreement”) BETWEEN AC Immune SA, EPFL Innovation Park, bâtiment B, 1015 Lausanne, Switzerland (the ‘‘Company“) AND [Name of Indemnitee] (the ‘‘Indemnitee“) the Company and the Indemnitee each a Party and together the "Parties" Recitals A) Both the Indemnitee and the Company recognize the increased risk of litigation and other claims being asserted against mem |
|
| March 16, 2023 |
Annual Report 2022Our goal is global leadership in Precision Medicine for the diagnosis and treatment of neurodegenerative diseases We are executing a clear business strategy built on three pillars: Accelerate development of novel therapeutics in AD with our partners Expand our strategic focus in Parkinson’s disease (PD) and non-AD neurodegenerative diseases, including NeuroOrphan indications and |
|
| March 16, 2023 |
Certification of Andrea Pfeifer pursuant to 17 CFR 240.13a-14(a) Exhibit 12.1 CERTIFICATION I, Andrea Pfeifer, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| March 16, 2023 |
Consent of PricewaterhouseCoopers SA EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-249655 and No. 333-255576) and on Form S-8 (No. 333-233019) of AC Immune SA of our report dated March 16, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appe |
|
| March 16, 2023 |
Certification of Andrea Pfeifer pursuant to 17 CFR 240.13a-14(b) and 18 U.S.C.1350 Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Andrea Pfe |
|
| March 16, 2023 |
Certification of Christopher Roberts pursuant to 17 CFR 240.13a-14(b) and 18 U.S.C.1350 Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Christophe |
|
| March 16, 2023 |
Certification of Christopher Roberts pursuant to 17 CFR 240.13a-14(a) Exhibit 12.2 CERTIFICATION I, Christopher Roberts, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 AC Immune SA (Name of Issuer) Common Shares, nominal value CHF 0.02 per share (Title of Class of Securities) H00263105 (CUSIP Number) Dece |
|
| February 14, 2023 |
ACIU / AC Immune SA / AFFiRiS AG - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 b26231sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) AC IMMUNE SA (Name of Issuer) Common Shares (Title of Class of Securities) H00263105 (CUSIP Number) October 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 10, 2023 |
SC 13G/A 1 ea173207-13ga4dieviniacimm.htm AMENDMENT NO. 4 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 4) AC IMMUNE SA (Name of Issuer) Common shares, nominal value CHF 0.02 p |
|
| January 27, 2023 |
ACIU / AC Immune SA / ELI LILLY & Co - SC 13G/A Passive Investment SC 13G/A 1 sc13gaacimmunesa.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 1)* AC Immune SA (Name of Issuer) Common Stock, par value CHF 0.02 per share (Title of Class of Securities) H00263105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check th |
|
| January 26, 2023 |
Exhibit 99.1 Press Release AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial · ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first low dose cohort · ACI-24.060 was generally well tolerated with no safety concerns observed · With these findings, dosing in the second higher dose Alzheim |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2023 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princi |
|
| November 30, 2022 |
6-K 1 dp1851056k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, |
|
| November 30, 2022 |
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development EXHIBIT 99.1 Press Release AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development · Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidate · Based on this new clinical data, ACI-35.030 has been selected for further development representing significant progress for the anti-pTau vaccine candidate · AC Immune vaccine |
|
| October 28, 2022 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (in CHF thousands) ? ? ? ? ? ? ? ? ? ? ? As of September 30, ? As of December 31, Balance Sheets Notes 2022 2021 ASSETS Non-current assets Property, plant and equipment 5 4,687 5,116 Right-of-use assets 6 2,491 2,914 Intangible asset 9 50,416 50,416 Long-term financial assets 6 361 363 Total non-current assets ? ? 57,955 58,809 ? ? ? ? |
|
| October 28, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ? Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princi |
|
| October 28, 2022 |
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update Exhibit 99.3 ? ? ? ? PRESS RELEASE ? AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update ? Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer?s disease and individuals with Down syndrome ? Received regulatory clearance to initiate an adaptive, biomarker-based Phase 2 s |
|
| September 26, 2022 |
Exhibit 99.1 Press Release AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer?s Disease ? AC Immune?s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer?s Disease (AD) ? AC Immune to receive a milestone payment from LMI for progress into late-stage product development Lausanne, Switzerland, September 26, 2022 ? AC Immune |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Prin |
|
| August 2, 2022 |
Exhibit 99.1 PRESS RELEASE Detailed data from the phase II Crenezumab Alzheimer?s Prevention Initiative Study in Autosomal Dominant Alzheimer?s Disease Presented at AAIC ? Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study ? As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, mul |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| July 28, 2022 |
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.3 Press Release AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Three clinical readouts delivered year to date; four more expected by year-end ? First patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study in patients with prodromal Alzheimer?s disease and individuals with Down syndrome ? Crenezumab API ADAD study results to be |
|
| July 28, 2022 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (in CHF thousands) Balance Sheets Notes As of June 30, 2022 As of December 31, 2021 ASSETS Non-current assets Property, plant and equipment 5 4,997 5,116 Right-of-use assets 6 2,632 2,914 Intangible asset 9 50,416 50,416 Long-term financial assets 6 361 363 Total non-current assets 58,406 58,809 Current assets Prepaid expenses 10 3,465 |
|
| July 28, 2022 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and si |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| June 24, 2022 |
EX-99.3 4 dp175826ex9903.htm EXHIBIT 99.3 Exhibit 99.3 Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these articles of association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I. Corporate Name, Principal Office, Du |
|
| June 24, 2022 |
Exhibit 99.1 NASDAQ: ACIU | Annual General Meeting, June 2022 ? 2022 AC Immune. Not to be used or reproduced without permission Pioneering Precision Medicine for Neurodegeneration NASDAQ: ACIU | Annual General Meeting, June 24, 2022 www.acimmune.com NASDAQ: ACIU | Annual General Meeting, June 2022 ? 2022 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contai |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal |
|
| June 24, 2022 |
AC Immune Holds Annual General Meeting of Shareholders Exhibit 99.2 Press Release AC Immune Holds Annual General Meeting of Shareholders Lausanne, Switzerland, June 24, 2022 ? AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appoi |
|
| June 16, 2022 |
PRESS RELEASE AC Immune provides update on Alzheimer?s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer?s disease Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer?s disease Numerical differences favoring crenezumab over placebo were observed across the co-p |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principal |
|
| May 25, 2022 |
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA Exhibit 99.1 Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA Date Friday, 24 June 2022 | 2 :30pm CEST | 8:30am EDT 1 Contents 3 Letter to Shareholders 5 Agenda and proposals 12 Organizational notes 15 Say on Pay Shareholder information on compensation proposal 2 Dear Shareholders, We are pleased to announce AC Immune?s 6th Annual General Meeting (AGM) as a public comp |
|
| May 25, 2022 |
EXHIBIT 99.2 1 U P X AC Immune SA Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 0 3N9OD + + q IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Annual General Meeting Proxy Card Proposals - The Board of Directors of the Company recommends that you vote your shares ?FOR? Agenda Ite |
|
| May 19, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-227016 PROSPECTUS SUPPLEMENT (To Prospectus dated August 24, 2018) 18,041,000 Common Shares Offered by the Selling Shareholders AC IMMUNE SA (incorporated in Switzerland) The selling shareholders listed in this prospectus supplement (the ?Selling Shareholders?) may offer and sell up to 18,041,000 common shares. Our common shares are listed on t |
|
| April 28, 2022 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three months |
|
| April 28, 2022 |
Exhibit 99.3 Press Release AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine First images of alpha-synuclein in patients? brains presented at AD/ |
|
| April 28, 2022 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (in CHF thousands) Balance Sheets Notes As of March 31, 2022 As of December 31, 2021 ASSETS Non-current assets Property, plant and equipment 5 4,908 5,116 Right-of-use assets 6 2,774 2,914 Intangible asset 8 50,416 50,416 Long-term financial assets 6 363 363 Total non-current assets 58,461 58,809 Current assets Prepaid expenses 9 2,805 |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| April 8, 2022 |
Exhibit 99.1 Press Release AC Immune Reports Changes to Senior Management Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO Julian Snow promoted to Vice President, U.S. Finance & Corporate Development Lausanne, Switzerland, April 8, 2022 ? AC Immune SA |
|
| March 22, 2022 |
Exhibit 12.1 CERTIFICATION I, Andrea Pfeifer, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the p |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 22, 2022 |
Exhibit 13.2 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA?s annual report on Form 20-F for the year ended December 31, 2019 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Joerg Horn |
|
| March 22, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-15.1 9 brhc10035387ex15-1.htm EXHIBIT 15.1 EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-249655 and No. 333-255576) and on Form S-8 (No. 333-233019) of AC Immune SA of our report dated March 22, 2022 relating to the consolidated financial statements and the effectivene |
|
| March 22, 2022 |
Exhibit 99.3 Statutory Financial Statements (Swiss CO) 1 January - 31 December 2021 Financial Statements 2 Notes to the Financial Statements 4 AC Immune SA EPFL Innovation Park 1015 Lausanne / Ecublens Switzerland AC Immune SA Ecublens Report of the statutory auditor to the General Meeting on the financial statements 2021 AC Immune SA, Ecublens Report of the statutory auditor to the General Meetin |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of principa |
|
| March 22, 2022 |
Exhibit 12.2 CERTIFICATION I, Joerg Hornstein, certify that: 1. I have reviewed this annual report on Form 20-F of AC Immune SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the |
|
| March 22, 2022 |
Exhibit 99.1 PRESS RELEASE AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial in patients with Alzheimer |
|
| March 22, 2022 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.2 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Audited consolidated financial statements ? AC IMMUNE SA Report of independent registered public accounting firm Consolidated Balance Sheets as of December 31, 2021 and 2020 F-3 Consolidated Statements of Income/(Loss) and Consolidated Statements of Comprehensive Income/(Loss) for the fiscal years ended December 31, 2021, 2020 and 2019 F-4 Co |
|
| March 22, 2022 |
Exhibit 13.1 CERTIFICATION The certification set forth below is being submitted in connection with AC Immune SA?s annual report on Form 20-F for the year ended December 31, 2019 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code. Andrea Pfe |
|
| March 22, 2022 |
Exhibit 99.4 Compensation Report in Accordance with the Ordinance against Excessive Compensation in Stock Exchange Listed Companies (Ordinance) Contents ? Report of the Statutory Auditor ? Compensation of the Board of Directors ? Compensation of the Members of the Executive Management ? Equity Incentive Plans of the Board of Directors and the Members of the Executive Management Annex ? Compensatio |
|
| March 22, 2022 |
Exhibit 3.1 ARTICLES OF ASSOCIATION of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these articles of association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec si?ge ? Ecublens (VD) La version fran?aise de ces statuts fait foi. I. CORPORATE NAME, PRINCIPAL OFFICE, DURATION AND PURPOSE OF THE COMPANY I. RAISON |
|
| March 22, 2022 |
Exhibit 4.18 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), as of March 22, 2022. The following description of the terms of our common shares is not meant to be co |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principa |
|
| March 16, 2022 |
Exhibit 99.1 Press Release AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson?s disease, Lewy Body Dementia, |
|
| February 14, 2022 |
ACIU / AC Immune SA / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) AC Immune SA (Name of Issuer) Common Shares, par value CHF 0.02 per share (Title of Class of Securities) H00263105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 AC Immune SA (Name of Issuer) Common Shares, par value CHF 0.02 (Title of Class of Securities) H00263105 (CUSIP Number) December 31, 2021 |
|
| November 12, 2021 |
EX-99.1 2 dp161675ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-st |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| November 8, 2021 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.2 Management?s Discussion and Analysis of Financial Condition and Results of Operations This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial information as of and for the three and ni |
|
| November 8, 2021 |
EX-99.4 5 dp161140ex9904.htm EXHIBIT 99.4 Exhibit 99.4 Articles of Association of AC Immune SA (AC Immune AG) (AC Immune Ltd) with registered office in Ecublens (VD) The French version of these articles of association shall prevail. STATUTS de AC Immune SA (AC Immune AG) (AC Immune Ltd) avec siège à Ecublens (VD) La version française de ces statuts fait foi. I. Corporate Name, Principal Office, Du |
|
| November 8, 2021 |
EX-99.3 4 dp161140ex9903.htm EXHIBIT 99.3 Exhibit 99.3 Press Release AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led by key |
|
| November 8, 2021 |
Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (in CHF thousands) Balance Sheets Notes As of September 30, 2021 As of December 31, 2020 ASSETS Non-current assets Property, plant and equipment 5 5,054 4,416 Right-of-use assets 6 2,572 2,223 Long-term accrued income 3 31 ? Long-term financial assets 8 363 334 Total non-current assets 8,020 6,973 Current assets Prepaid expenses 7 1,93 |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princ |
|
| October 29, 2021 |
6-K 1 dp1608356k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, |
|
| October 29, 2021 |
EX-99.1 2 dp160835ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a le |
|
| October 15, 2021 |
6-K 1 dp1594576k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, |
|
| October 7, 2021 |
Exhibit 99.1 Notice of the Extraordinary General Meeting (EGM) of 29 October 2021 To the Shareholders of AC Immune SA 1 Date Friday, 29 October 2021 | 11:00 AM CEST Contents 4 Letter to Shareholders 5 Agenda and proposals 12 Organizational notes 3 Dear Shareholders, We are pleased to welcome you to our Extraordinary General Meeting and take this opportunity to propose to you the appointment as boa |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-37891 AC IMMUNE SA (Exact name of registrant as specified in its charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of princi |
|
| October 7, 2021 |
Exhibit 99.2 AC Immune SA MMMMMMMMMMMMMM C123456789 000004 ENDORSEMENTLINE SACKPACK 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 Your vote matters – here’s how to vote! You may vote online instead of mailing this card. Votes submitted electronically |
|
| August 31, 2021 |
EX-99.1 2 dp157141ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 First evidence of clinical activity in tau-ta |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| August 5, 2021 |
EX-24.1 3 ex241.htm EXHIBIT 24.1 Exhibit 24.1 POWER OF ATTORNEY Effective as of the date first set forth below, the undersigned does hereby appoint Ms. Martina Hopitzan, born 2 June 1971, and/or Mr. Marco Steiner, born 27 April 1977, and/or Mr. Johannes Feilmair, born 8 March 1991, and/or Mr. Fabian Larcher, born 17 July 1995, with full power of substitution, as the true and lawful attorney of the |
|
| August 5, 2021 |
EX-1 2 ex1.htm EXHIBIT 1 Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G is being filed, and any amendments thereto will be filed, with respect to the ownership by each of the undersigned of shares of AC Immune SA. Each of the undersigned acknowledge |
|
| August 5, 2021 |
ACIU / AC Immune SA / AFFiRiS AG Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AC IMMUNE SA (Name of Issuer) Common Shares (Title of Class of Securities) H00263105 (CUSIP Number) July 26, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1( |
|
| August 4, 2021 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations EX-99.2 6 dp155670ex9902.htm EXHIBIT 99.2 Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this in conjunction with our unaudited interim condensed consolidated financial |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Princip |
|
| August 4, 2021 |
EX-10.2 3 dp155670ex1002.htm EXHIBIT 10.2 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAD BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[*****]”. Exhibit 10.2 Convertible Note Agreement (the "Agreement |
